 Connection
Guido Tricot to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Guido Tricot has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.616 |
|
|
|
-
Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis. 2007 Oct; 18(7):595-8.
Score: 0.194
-
Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007 Sep; 82(9):831-3.
Score: 0.193
-
Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma. 2006 May; 6(6):469-74.
Score: 0.176
-
Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct; 131(1):71-3.
Score: 0.169
-
Fassas AB, Tricot G. Tandem transplants in the treatment of multiple myeloma. Pro. Clin Adv Hematol Oncol. 2004 May; 2(5):303-4.
Score: 0.153
-
Strouse C, Mott SL, Smith BJ, Magalhaes-Silverman M, Farooq U, Zhan F, Jethava Y, Tricot G. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients. Bone Marrow Transplant. 2024 01; 59(1):128-130.
Score: 0.147
-
Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9.
Score: 0.145
-
Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol. 2002 Dec; 29(6 Suppl 17):26-33.
Score: 0.139
-
Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol. 2002 Oct; 119(1):164-8.
Score: 0.137
-
Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15; 100(4):1168-71.
Score: 0.136
-
Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma. 2002 Jun; 43(6):1267-71.
Score: 0.134
-
Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, Xu Z, Sun X, Chang S, Gao L, Tao Y, Xu H, Xie Y, Xiao W, Yu D, Kong Y, Chen G, Sun X, Lian F, Zhang N, Wu X, Mao Z, Zhan F, Zhu W, Shi J. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression. Cancer Res. 2020 02 01; 80(3):536-548.
Score: 0.112
-
Jethava YS, Barlogie B, Tricot GJ. Drug Combinations with Transplantation for Myeloma. N Engl J Med. 2017 07 06; 377(1):91-2.
Score: 0.096
-
Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016 Jan 12; 7(2):1598-607.
Score: 0.086
-
Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD, Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008 Mar; 140(6):625-34.
Score: 0.050
-
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007 Jul; 138(2):176-85.
Score: 0.048
-
van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 01; 110(3):827-32.
Score: 0.047
-
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30.
Score: 0.044
-
Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006 Apr 01; 107(7):2633-8.
Score: 0.043
-
Fassas AB, Kiwan E, Roberts J, Burr T, Tricot G, Anaissie E, Barlogie B. Metronomic chemoimmunotherapy in a patient with refractory Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2005 Nov; 46(11):1675-7.
Score: 0.043
-
Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol. 2005 Aug 01; 23(22):5217-23.
Score: 0.041
-
Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707.
Score: 0.038
-
Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5.
Score: 0.036
-
Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56.
Score: 0.035
-
Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
Score: 0.035
-
Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002 Apr; 117(1):103-8.
Score: 0.033
-
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
Score: 0.016
-
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42.
Score: 0.014
-
Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis. 2009 Jul; 20(5):337-9.
Score: 0.014
-
Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007 Dec 01; 13(23):7073-9.
Score: 0.012
-
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar 20; 25(9):1121-8.
Score: 0.012
-
Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64.
Score: 0.011
-
Miceli M, Atoui R, Walker R, Mahfouz T, Mirza N, Diaz J, Tricot G, Barlogie B, Anaissie E. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol. 2004 May 15; 22(10):1949-56.
Score: 0.010
-
Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003 Jan; 120(1):44-52.
Score: 0.009
-
Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4(6):379-98.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|